<DOC>
	<DOCNO>NCT00485407</DOCNO>
	<brief_summary>The purpose trial test value dose increase patient residual ADHD symptom treatment usual target dose atomoxetine</brief_summary>
	<brief_title>Guiding Dose Increases Patients Incompletely Responsive Usual Doses Atomoxetine</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<criteria>Outpatients least 6 year age 16 year age Visit 1 Patients must meet DSMIV diagnostic criterion ADHD ( subtype ) Patients must laboratory result show significant abnormality ( significant would include laboratory deviation require acute medical intervention medical evaluation ) Patients must normal intelligence assess investigator ( , without general impairment intelligence likely , investigator 's judgment , achieve score great equal 70 IQ test ) Patients must able swallow capsule Patients weigh less 25 kg great 70 kg study entry Patients current past Bipolar I II disorder , psychosis , autism , Asperger 's syndrome , pervasive developmental disorder Patients history seizure disorder ( febrile seizure ) patient take ( currently take ) anticonvulsant seizure control Patients history severe allergies 1 class medication multiple adverse drug reaction Patients cardiovascular disease condition could aggravate increased heart rate increase blood pressure</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>June 2007</verification_date>
</DOC>